哈尔滨医药2024,Vol.44Issue(6) :15-17.DOI:10.3969/j.issn.1001-8131.2024.06.004

托伐普坦联合氟伐他汀对慢性心力衰竭患者血管内皮功能及血清Nexilin、CASP3水平的影响

Effects of Tolvasttan Combined with Fluvastatin on Vascular Endothelial Function and Serum Nexilin and CASP3 Levels in Patients with Chronic Heart Failure

李福斌 李秀芳 王晓利
哈尔滨医药2024,Vol.44Issue(6) :15-17.DOI:10.3969/j.issn.1001-8131.2024.06.004

托伐普坦联合氟伐他汀对慢性心力衰竭患者血管内皮功能及血清Nexilin、CASP3水平的影响

Effects of Tolvasttan Combined with Fluvastatin on Vascular Endothelial Function and Serum Nexilin and CASP3 Levels in Patients with Chronic Heart Failure

李福斌 1李秀芳 1王晓利1
扫码查看

作者信息

  • 1. 焦作市第五人民医院内科,河南 焦作 454000
  • 折叠

摘要

目的 研究托伐普坦联合氟伐他汀对慢性心力衰竭(CHF)患者血管内皮功能及血清Nexilin、半胱氨酸天冬氨酸蛋白酶-3(CASP3)水平的影响.方法 回顾性分析 86例CHF患者资料,按不同治疗方案分为对照组(接受氟伐他汀治疗)、观察组(接受托伐普坦+氟伐他汀治疗),各 43 例.比较两组临床疗效、心功能[每搏量(SV)、心肌能量消耗(MEE)、左心房内径(LAD)、左室射血分数(LVEF)]、血管内皮功能[一氧化氮(NO)、降钙素基因相关肽(CGRP)、内皮素-1(ET-1)]、血清Nexilin、CASP3及不良反应.结果 研究组临床总有效率(90.70%)高于对照组(72.09%)(P<0.05);与治疗前比较,两组MEE、LAD均降低,SV、LVEF均升高,且研究组更为显著(P<0.05);与治疗前相比,治疗后研究组NO、CGRP明显升高,ET-1 明显降低(P<0.05);与治疗前相比,研究组治疗后Nexilin、CASP3 降低幅度大于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论 托伐普坦联合氟伐他汀治疗CHF效果显著,可下调Nexilin、CASP3表达,改善血管内皮功能,增强心功能,安全性高.

Abstract

Objective To investigate the effects of tolvasttan combined with fluvastatin on vascular endothelial function and serum levels of Nexilin and cysteine aspartic protease-3(CASP3)in patients with chronic heart failure(CHF).Methods The data of 86 patients with CHF were retrospectively analyzed,and they were divided into control group(receiving fluvastatin treatment)and observation group(receiving torvasttan+fluvastatin treatment)according to different treatment plans,with 43 cases in each group.The clinical efficacy,cardiac function[stroke volume(SV),myocardial energy expenditure(MEE),left atrial diameter(LAD),left ventricular ejection fraction(LVEF)],vascular endothelial function[nitric oxide(NO),calcitonin gene-related peptide(CGRP),endothelin-1(ET-1)],serum Nexilin,CASP3 and adverse reactions were compared between the two groups.Results The total effective rate of the study group(90.70%)was higher than that of the control group(72.09%)(P<0.05).Compared with before treatment,MEE and LAD were decreased in both groups,SV and LVEF were increased,and the study group was more significant(P<0.05).Compared with before treatment,NO and CGRP were significantly increased and ET-1 was significantly decreased in the group after treatment(P<0.05).Compared with before treatment,the reduction of Nexilin and CASP3 in the study group after treatment was greater than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Torvasttan combined with fluvastatin is effective in the treatment of CHF,it can down-regulate the expression of Nexilin and CASP3,improve vascular endothelial function,enhance cardiac function,and has high safety.

关键词

慢性心力衰竭/托伐普坦/氟伐他汀/血管内皮功能/半胱氨酸天冬氨酸蛋白酶-3/Nexilin

Key words

Chronic heart failure/Tolvaptan/Fluvastatin/Vascular endothelial function/Cysteine aspartate protease-3/Nexilin

引用本文复制引用

出版年

2024
哈尔滨医药
哈尔滨市医学会

哈尔滨医药

影响因子:0.697
ISSN:1001-8131
段落导航相关论文